MA35428B1 - Proteines et peptides podifies - Google Patents

Proteines et peptides podifies

Info

Publication number
MA35428B1
MA35428B1 MA36807A MA36807A MA35428B1 MA 35428 B1 MA35428 B1 MA 35428B1 MA 36807 A MA36807 A MA 36807A MA 36807 A MA36807 A MA 36807A MA 35428 B1 MA35428 B1 MA 35428B1
Authority
MA
Morocco
Prior art keywords
peptides
proteins
variable domains
molecules
modified
Prior art date
Application number
MA36807A
Other languages
English (en)
Inventor
Claire Ashman
Mary Birchler
Wildt Rudolf M T De
Claire Holland
Alan Peter Lewis
Peter Morley
Thomas Sandal
Michael Steward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1121226.3A external-priority patent/GB201121226D0/en
Priority claimed from GBGB1121236.2A external-priority patent/GB201121236D0/en
Priority claimed from GBGB1121233.9A external-priority patent/GB201121233D0/en
Priority claimed from PCT/EP2012/064632 external-priority patent/WO2013014208A2/fr
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA35428B1 publication Critical patent/MA35428B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

La présente invention concerne des protéines et peptides modifiés qui ont une capacité réduite à se lier à des anticorps préexistants. De telles molécules protéiques/peptidiques modifiées peuvent comprendre des additions, extensions ou étiquettes et/ou certaines substitutions d'acides aminés c-terminales. De telles molécules modifiées (par exemple des fusions ou des conjugués) comprennent des protéines, des peptides, des molécules de liaison à un antigène, des anticorps ou des fragments d'anticorps, tels que des domaines variables uniques, par exemple des domaines variables uniques d'immunoglobuline (anticorps) humaine, et également des domaines variables uniques issus de sources non-humaines, telles qu'un lama ou un chameau, par exemple un vhh comprenant un nanocorps
MA36807A 2011-08-17 2014-03-06 Proteines et peptides podifies MA35428B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161524488P 2011-08-17 2011-08-17
GBGB1121226.3A GB201121226D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides
GBGB1121236.2A GB201121236D0 (en) 2011-12-12 2011-12-12 Proteins and peptides
GBGB1121233.9A GB201121233D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides
PCT/EP2012/064632 WO2013014208A2 (fr) 2011-07-27 2012-07-25 Constructions de liaison à un antigène
PCT/EP2012/065782 WO2013024059A2 (fr) 2011-08-17 2012-08-13 Protéines et peptides modifiés

Publications (1)

Publication Number Publication Date
MA35428B1 true MA35428B1 (fr) 2014-09-01

Family

ID=47715521

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36807A MA35428B1 (fr) 2011-08-17 2014-03-06 Proteines et peptides podifies

Country Status (25)

Country Link
US (3) US10808040B2 (fr)
EP (3) EP2987806A3 (fr)
JP (3) JP6297976B2 (fr)
KR (2) KR102143506B1 (fr)
CN (2) CN103917557B (fr)
AR (1) AR087521A1 (fr)
AU (3) AU2012296961B2 (fr)
BR (1) BR112014003679B1 (fr)
CA (1) CA2845029A1 (fr)
CO (1) CO7020851A2 (fr)
DO (1) DOP2014000029A (fr)
EA (1) EA027160B1 (fr)
ES (1) ES2813432T3 (fr)
HK (1) HK1214281A1 (fr)
IL (1) IL230918A0 (fr)
MA (1) MA35428B1 (fr)
MX (1) MX2014001883A (fr)
MY (1) MY167125A (fr)
PE (1) PE20141522A1 (fr)
PH (1) PH12014500380A1 (fr)
SG (2) SG10201605891TA (fr)
TW (1) TW201321405A (fr)
UA (1) UA118833C2 (fr)
UY (1) UY34254A (fr)
WO (1) WO2013024059A2 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
EP2621953B1 (fr) 2010-09-30 2017-04-05 Ablynx N.V. Matières biologiques associées à c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP4350345A3 (fr) * 2011-06-23 2024-07-24 Ablynx N.V. Techniques de prediction, de detection et de reduction d'interferences de proteines specifiques dans des dosages impliquant des domaines variables simples d'immunoglobulines
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
EP2944654A1 (fr) * 2011-06-23 2015-11-18 Ablynx N.V. Techniques de prédiction, de détection et de réduction d'une interférence de protéines spécifiques dans des analyses impliquant des domaines variables simples d'immunoglobulines
EP3466972B1 (fr) 2011-06-23 2026-03-04 Ablynx NV Protéines de liaison de l'albumine sérique
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20140161796A1 (en) * 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
WO2014111550A1 (fr) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Protéines de liaison modifiées anti-albumine sérique
WO2015104322A1 (fr) * 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Traitement de maladies inflammatoires avec des antagonistes anti-tnfr1 non compétitifs
AU2015261467B2 (en) 2014-05-16 2020-12-17 Ablynx Nv Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
SG11201609162SA (en) 2014-05-16 2016-12-29 Ablynx Nv Improved immunoglobulin variable domains
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
AP2017009823A0 (en) * 2014-09-26 2017-03-31 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
WO2016150845A1 (fr) * 2015-03-20 2016-09-29 Ablynx Nv Domaines variables uniques d'immunoglobuline glycosylés
MX2017012662A (es) 2015-03-31 2018-05-11 Vhsquared Ltd Polipeptidos.
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
CN114106178A (zh) 2015-07-16 2022-03-01 印希比股份有限公司 多价和多特异性结合dr5的融合蛋白
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
ES2904553T3 (es) * 2015-10-30 2022-04-05 Hoffmann La Roche Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
CN108350069B (zh) * 2015-10-30 2021-11-12 埃博灵克斯股份有限公司 针对il-23的多肽
AU2016352695B2 (en) * 2015-11-12 2023-07-27 Ablynx Nv Improved P2X7 receptor binders and polypeptides comprising the same
NO2768984T3 (fr) * 2015-11-12 2018-06-09
ES2905912T3 (es) 2015-11-13 2022-04-12 Ablynx Nv Dominios variables de inmunoglobulina de unión a albúmina sérica mejorados
MY189590A (en) 2015-11-18 2022-02-18 Merck Sharp & Dohme Ctla4 binders
CA3003777A1 (fr) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Liants pd1/ctla4
CA3132021C (fr) * 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Liants de pd1 et/ou lag3
EP3377525A2 (fr) 2015-11-18 2018-09-26 Ablynx NV Liants d'albumine sérique améliorés
CN108473561B (zh) 2015-11-27 2022-12-16 埃博灵克斯股份有限公司 抑制cd40l的多肽
KR102802241B1 (ko) 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
GB201522539D0 (en) 2015-12-21 2016-02-03 Hexcel Composites Ltd Improvements in or relating to electrically conducting materials
CN109313183B (zh) * 2016-06-23 2022-10-21 埃博灵克斯股份有限公司 免疫球蛋白单可变结构域的改进的药代动力学测定
WO2018060453A1 (fr) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
EP3551656A1 (fr) 2016-12-07 2019-10-16 Ablynx NV Domaines variables uniques d'immunoglobuline se liant à l'albumine sérique améliorée
CN117285623A (zh) 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
DK3571224T3 (da) 2017-01-17 2024-11-11 Ablynx Nv Forbedrede serumalbuminbindere
AU2018241286B2 (en) 2017-03-31 2025-03-13 Ablynx N.V. Improved immunogenicity assays
TWI887192B (zh) 2017-05-31 2025-06-21 比利時商艾伯林克斯公司 拮抗腫瘤細胞中wnt訊息傳導之多肽
WO2019051102A2 (fr) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Protéines de liaison à activation conditionnelle restreinte
CA3075367A1 (fr) 2017-09-27 2019-04-04 Elasmogen Ltd Molecules de liaison specifiques
CN111670202A (zh) * 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
EP3569618A1 (fr) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisation d'anticorps cd73
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
AR115730A1 (es) * 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
CN109096394B (zh) * 2018-09-21 2021-11-05 成都阿帕克生物科技有限公司 一种抗葡萄球菌蛋白a的b亚单位的纳米抗体及核酸分子和应用
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
GB201818460D0 (en) * 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
WO2020181140A1 (fr) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Protéines de liaison à activation conditionnelle limitée
CN114514243B (zh) 2019-06-21 2025-01-24 索瑞索制药公司 多肽
EP3986570A1 (fr) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Compositions
EP3986571A1 (fr) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
EP4073122A4 (fr) 2019-12-11 2024-03-27 Cullinan Oncology, Inc. Anticorps anti-cd19 et protéines de liaison multi-spécifiques
JP7734132B2 (ja) * 2019-12-11 2025-09-04 カリナン セラピューティクス インコーポレイテッド 抗血清アルブミン抗体
AR121706A1 (es) * 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
US20240026011A1 (en) 2020-08-17 2024-01-25 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN117903303A (zh) * 2020-08-20 2024-04-19 南京融捷康生物科技有限公司 Il-5的结合分子及其应用
JP2023541816A (ja) * 2020-08-27 2023-10-04 イノージ・セラピューティクス・コーポレイション 自己免疫性疾患および癌を治療するための方法および組成物
JP2023540533A (ja) 2020-09-04 2023-09-25 武田薬品工業株式会社 ヒト血清アルブミンドメインを有する、制約され、条件付きで活性化された結合タンパク質構築物
WO2022081460A1 (fr) * 2020-10-12 2022-04-21 Janssen Biotech, Inc. Matières et procédés biosynthétiques pour le biotransport multidirectionnel
CN113307869B (zh) * 2020-10-30 2023-01-06 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
MX2023006869A (es) 2020-12-14 2023-08-14 Takeda Pharmaceuticals Co Proteinas de union condicionalmente biespecificas.
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
US20240199744A1 (en) 2021-04-06 2024-06-20 Takeda Pharmaceutical Company Limited Therapeutic methods using constrained conditionally activated binding proteins
TW202330596A (zh) * 2021-11-29 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 經修飾的蛋白或多肽
WO2023110190A1 (fr) 2021-12-13 2023-06-22 Heraeus Medical Gmbh Tests et procédés de détection d'une infection bactérienne
EP4469474A4 (fr) * 2022-01-27 2026-05-20 Janssen Biotech Inc Compositions de protéines améliorées
WO2023164551A1 (fr) 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Protéines de liaison bispécifiques de manière conditionnelle
KR20250042176A (ko) 2022-07-27 2025-03-26 아블린쓰 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드
EP4357778A1 (fr) 2022-10-20 2024-04-24 Heraeus Medical GmbH Traitement d'infections microbiennes diagnostiquées à l'aide du d-lactate de biomarqueur
CN115819599B (zh) * 2022-11-29 2024-01-16 江苏耀海生物制药有限公司 一种利用重组大肠杆菌分泌表达纳米抗体Cablivi的方法
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
IL323035A (en) 2023-03-14 2025-10-01 Odyssey Therapeutics Inc Anti-CD25 antigen-binding proteins and their uses
EP4698909A1 (fr) * 2023-04-20 2026-02-25 Xentria, Inc. Procédés de détection d'un anticorps anti-médicament (ada) contre un anticorps anti-tnf alpha
CN121511255A (zh) 2023-05-17 2026-02-10 奥德赛治疗股份有限公司 经修饰的单结构域抗体
KR20260032566A (ko) 2023-06-29 2026-03-09 오디세이 테라퓨틱스, 인코포레이티드 항-trailr2 항원-결합 단백질 및 그의 용도
CN121443644A (zh) 2023-07-05 2026-01-30 阿布林克斯有限公司 用于治疗IgG相关疾病和障碍的改善的FcRn拮抗剂
IL326617A (en) 2023-08-30 2026-04-01 Xilio Dev Inc Masked IL-2 cytokines and methods of using them
US20250092109A1 (en) 2023-08-30 2025-03-20 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof
CN121986112A (zh) 2023-09-22 2026-05-05 阿布林克斯有限公司 二价和多价白蛋白结合剂
WO2025080751A2 (fr) 2023-10-13 2025-04-17 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-cdh17 et leurs utilisations
CN119173537A (zh) * 2024-01-03 2024-12-20 苏州智核生物医药科技有限公司 经修饰的免疫球蛋白单一可变结构域
WO2025151752A1 (fr) 2024-01-10 2025-07-17 Xilio Development, Inc. Cytokines il-2 masquées et procédés d'utilisation associées
WO2025167664A1 (fr) * 2024-02-07 2025-08-14 原启生物科技(上海)有限责任公司 Protéine de liaison à l'antigène ror1 et son utilisation
WO2025189977A1 (fr) * 2024-03-13 2025-09-18 寻济生物科技（北京）有限公司 Construction de fusion anti-vegfa, son procédé de préparation et son utilisation
TW202602941A (zh) 2024-04-10 2026-01-16 美商奧迪希治療公司 抗tnfr2抗原結合蛋白及其用途
WO2025255435A2 (fr) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène dirigées contre l'albumine sérique et leurs utilisations
WO2025255558A2 (fr) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-lymphopoïétine stromale thymique (tslp) et leurs utilisations
WO2026006708A2 (fr) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-cd25 et leurs utilisations
WO2026006809A1 (fr) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Molécules multispécifiques se liant à tnfr2 et cd25 et leurs utilisations

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP1600459A3 (fr) * 2002-06-28 2005-12-07 Domantis Limited Ligand
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
MX2007014564A (es) * 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
WO2006129843A2 (fr) * 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Molecule de capture de substance cible
US20100323905A1 (en) * 2005-09-23 2010-12-23 Academisch Ziekenhuis Leiden Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
KR20080077237A (ko) * 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷
WO2007085814A1 (fr) 2006-01-24 2007-08-02 Domantis Limited Protéines de fusion contenant des jonctions naturelles
CA2666599A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
US20100143340A1 (en) * 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
EP2158318A2 (fr) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Régions fc simple chaîne, polypeptides de liaison comportant de telles régions, et procédés correspondants
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
AU2008259590A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2009068631A1 (fr) 2007-11-27 2009-06-04 Ablynx N.V. Procédé d'obtention de produits de construction de polypeptide comprenant au moins deux anticorps à domaine unique
EP2222709B1 (fr) 2007-11-30 2016-11-23 Glaxo Group Limited Produits de construction de liaison à un antigène
TW200938222A (en) 2007-12-13 2009-09-16 Glaxo Group Ltd Compositions for pulmonary delivery
CA2718081A1 (fr) 2008-03-21 2009-09-24 Ablynx Nv Agglutinants specifiques du facteur de von willebrand et methodes d'utilisation
US8020937B2 (en) * 2008-07-31 2011-09-20 Lear Corporation Layered technology for energy management of vehicle seating
CA2733742A1 (fr) * 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anticorps de domaines variants
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
WO2010100135A1 (fr) 2009-03-05 2010-09-10 Ablynx N.V. Nouveaux complexes dimères de liaison antigénique, méthodes d'obtention/non obtention et leurs utilisations
US8748581B2 (en) * 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
US9150640B2 (en) * 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
TW201132759A (en) * 2009-12-18 2011-10-01 Sanofi Aventis Novel antagonist antibodies and their FaB fragments against GPVI and uses thereof
EP2621953B1 (fr) * 2010-09-30 2017-04-05 Ablynx N.V. Matières biologiques associées à c-met
HUE031828T2 (en) * 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
EP2944654A1 (fr) * 2011-06-23 2015-11-18 Ablynx N.V. Techniques de prédiction, de détection et de réduction d'une interférence de protéines spécifiques dans des analyses impliquant des domaines variables simples d'immunoglobulines
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
WO2014111550A1 (fr) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Protéines de liaison modifiées anti-albumine sérique

Also Published As

Publication number Publication date
US10808040B2 (en) 2020-10-20
AU2012296961B2 (en) 2017-02-16
JP6297976B2 (ja) 2018-03-20
TW201321405A (zh) 2013-06-01
MX2014001883A (es) 2014-05-27
WO2013024059A2 (fr) 2013-02-21
CN103917557A (zh) 2014-07-09
SG10201605891TA (en) 2016-09-29
DOP2014000029A (es) 2014-10-31
EP2744822B1 (fr) 2020-06-24
EA201490262A1 (ru) 2014-09-30
KR20140054262A (ko) 2014-05-08
CN103917557B (zh) 2018-03-20
JP2018117623A (ja) 2018-08-02
AU2019201505A1 (en) 2019-03-28
US20250136721A1 (en) 2025-05-01
UA118833C2 (uk) 2019-03-25
PE20141522A1 (es) 2014-11-17
BR112014003679A2 (pt) 2017-03-07
EP2987806A2 (fr) 2016-02-24
ES2813432T3 (es) 2021-03-23
HK1214281A1 (en) 2016-07-22
AR087521A1 (es) 2014-03-26
UY34254A (es) 2013-04-05
WO2013024059A9 (fr) 2014-04-03
CO7020851A2 (es) 2014-08-11
EP2987806A3 (fr) 2016-07-13
KR102162413B1 (ko) 2020-10-07
CN108178800B (zh) 2022-06-17
JP2014525752A (ja) 2014-10-02
US20140227259A1 (en) 2014-08-14
AU2016277685A1 (en) 2017-01-19
AU2016277685B2 (en) 2019-03-28
CN108178800A (zh) 2018-06-19
NZ621203A (en) 2016-03-31
JP6979446B2 (ja) 2021-12-15
WO2013024059A3 (fr) 2014-05-30
EP3339322A3 (fr) 2018-10-31
IL230918A0 (en) 2014-03-31
PH12014500380A1 (en) 2022-05-02
BR112014003679B1 (pt) 2022-08-30
EP3339322A2 (fr) 2018-06-27
MY167125A (en) 2018-08-13
CA2845029A1 (fr) 2013-02-21
EP2744822A2 (fr) 2014-06-25
US20210017293A1 (en) 2021-01-21
KR102143506B1 (ko) 2020-08-12
JP2020054374A (ja) 2020-04-09
EA027160B1 (ru) 2017-06-30
AU2012296961A1 (en) 2014-03-13
SG2014010482A (en) 2014-04-28
KR20190113996A (ko) 2019-10-08

Similar Documents

Publication Publication Date Title
EA201490262A1 (ru) Модифицированные белки и пептиды
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
Qi et al. Characterization of UO22+ binding to osteopontin, a highly phosphorylated protein: insights into potential mechanisms of uranyl accumulation in bones
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
EA201100527A1 (ru) Биологические продукты
MA33387B1 (fr) Polypeptides et procede de traitement
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
EP2352523A4 (fr) Anticorps anti-cd19 améliorés
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
MA34527B1 (fr) Anticorps contre la metalloproteinase de matrice 9
IL200373A (en) A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans
UA99701C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
WO2009010539A3 (fr) Recepteur de l'interleukine-6 (il-6) derive de macaca fascicularis
MY155144A (en) NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
EP2403871A4 (fr) Anticorps et épitopes spécifiques d'une protéine prion dite tordue
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
BR112022005410A2 (pt) Métodos e composições compreendendo um anticorpo monoclonal anti-ctla4 com proteínas de célula hospedeira reduzidas e estabilidade de polissorbato 80 aumentada